On October 5, 2023 Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, reported its plans to host a Virtual R&D Event with Key Opinion Leaders (KOLs) on October 17, 2023 (Press release, Vivoryon Therapeutics, OCT 5, 2023, View Source [SID1234635690]). In addition, the Company’s management will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event details:

Jefferies Biotech CNS/Neuro Summit (October 11 – 12, 2023)

Date: October 11, 2023

Presentation time: 2:00pm EDT / 8:00pm CEST

Venue: New York; NY, USA

Virtual R&D Event with Key Opinion Leaders

Date: October 17, 2023
Time: 7:30am EDT / 1:30pm CEST
Featured presentations and a moderated panel discussion on the design and rationale of the VIVIAD Phase 2b study of varoglutamstat in Alzheimer’s disease followed by Q&A
For further information and pre-registration, please visit View Source

Webcasts of the conference presentation and the Virtual R&D Event will be available via the "Presentations & Webcasts" page in the Investor Relations section on the Company’s website at www.vivoryon.com and will be archived on the Company’s website for 90 days (conference), respectively one year (R&D Event) following the events.